Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bellicum Pharmaceuticals Inc.
Headquarters: Houston, TX, United States of America
Website: http://www.bellicum.com
Year Founded: 2004
Status: Public
Industry Sector: HealthTechnology
CEO: Dave Maggio
Number Of Employees: 13
Enterprise Value: $18,395,300
PE Ratio: -0.06
Exchange/Ticker 1: NASDAQ:BLCM
Exchange/Ticker 2: N/A
Latest Market Cap: $889,600
BioCentury | Nov 1, 2024
Discovery & Translation
Dynamic range: the key to MeiraGTx’s quest to control genes with pills
Company’s first goals are to improve GLP-1s and CAR Ts with the ability to go from zero to very high expression, on demand
BioCentury | Jul 21, 2023
Management Tracks
Ann Lee-Karlon named CEO of EpiBiologics
Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio
BioCentury | Jun 2, 2023
Management Tracks
Illumina names Hologic’s MacMillan chair
Plus: New CEO at OBI and updates from Affini-T, Walking Fish and Bellicum
BioCentury | Mar 16, 2023
Deals
March 15 Quick Takes: Rival bid could upend Redx-Jounce deal
Plus: Dermavant’s Vtama meets Phase III endpoints, and updates from CMS, Aitia, Bellicum and more
BioCentury | Sep 3, 2021
Management Tracks
Civetta picks Roberts as CEO
Plus, management moves at Crinetics, OraSure, Silence, Avacta, Oncternal and more
BioCentury | Apr 16, 2021
Finance
April 15 Quick Takes: Co-founded by Springer and Kruse, GPCR play Tectonic raises $80M; plus AltruBio, Rapha, Benchling, BioAge, Amgen
Tectonic Therapeutic Inc. debuted with an $80 million series A round co-led by Vida Ventures, T.A. Springer, and Polaris Partners to discover and develop of GPCR-targeted therapies. Tectonic was
BioCentury | Mar 4, 2021
Management Tracks
Amazon exec Lathia joins Flagship-backed Valo as chief product officer; plus AavantiBio, CatalYm, Corcept, Vincerx, OnCusp and more
Flagship-backed cloud computing-based drug discovery and development company Valo Health LLC named Nish Lathia chief product officer. The 18-year veteran of Amazon.com Inc. (NASDAQ:AMZN) held a
BioCentury | Feb 13, 2021
Product Development
Howdy partner: MD Anderson’s evolving industry collaboration strategy
How the cancer center is choosing clinical trial partners and advancing new modalities
BioCentury | Jan 30, 2021
Deals
Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum
Three months after its lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc. and
BioCentury | Dec 9, 2020
Product Development
Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim
Amgen readies sotorasib for FDA Amgen Inc. (NASDAQ:AMGN) said it plans to submit an NDA for its closely watched KRAS inhibitor sotorasib by year-end to treat locally advanced or
Items per page:
1 - 10 of 93